BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Duchenne muscular dystrophy clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for Duchenne muscular dystrophy: 57 (32 sponsors; 6 newly posted in the last 180 days, 3 stopped in the last 180 days; 3 new-entrant sponsors). Momentum score 7.9, rank 81 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 2, Phase 1 3, Phase 2 30, Phase 3 11, Phase 4 3, N/A 8.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| Sarepta Therapeutics, Inc. SRPT | 6 | P3 2, P4 1, NA 2, P1 1 | 0 | 0 |
| Italfarmaco | 3 | P2 1, P3 2 | 0 | 0 |
| NS Pharma, Inc. | 5 | P3 1, P4 1, P2 3 | 1 | 1 |
| REGENXBIO Inc. RGNX | 3 | NA 2, P3 1 | 0 | 0 |
| Avidity Biosciences, Inc. | 2 | P2 1, P3 1 | 0 | 1 |
| Capricor Inc. CAPR | 2 | P3 1, P2 1 | 0 | 0 |
| Dyne Therapeutics DYN | 2 | P3 1, P2 1 | 1 | 0 |
| Solid Biosciences Inc. SLDB | 2 | P3 1, P2 1 | 0 | 1 |
| Pfizer PFE | 1 | P3 1 | 0 | 0 |
| Edgewise Therapeutics, Inc. EWTX | 3 | P2 3 | 0 | 2 |
| Entrada Therapeutics, Inc. TRDA | 3 | P2 3 | 1 | 0 |
| BioMarin Pharmaceutical BMRN | 2 | P2 2 | 0 | 1 |
| Hoffmann-La Roche | 2 | P2 2 | 0 | 1 |
| Satellos Bioscience, Inc. MSLE | 2 | P2 2 | 0 | 1 |
| Wave Life Sciences USA, Inc. WVE | 2 | P2 2 | 0 | 0 |
| AO GENERIUM new entrant | 1 | P2 1 | 1 | 0 |
| Belief BioMed (Beijing) Co., Ltd | 1 | P2 1 | 0 | 0 |
| Catalyst Pharmaceuticals, Inc. CATL | 1 | NA 1 | 0 | 0 |
| Daiichi Sankyo Co., Ltd. | 1 | P2 1 | 0 | 1 |
| Grünenthal GmbH new entrant | 1 | P2 1 | 1 | 0 |
| HuidaGene Therapeutics Co., Ltd. | 1 | EARLY_P1 1 | 0 | 0 |
| Insmed Gene Therapy LLC INSM | 1 | P1 1 | 0 | 0 |
| ITF Therapeutics LLC | 1 | NA 1 | 0 | 0 |
| Keros Therapeutics, Inc. KROS new entrant | 1 | P2 1 | 1 | 0 |
| MED Institute Inc. | 1 | P2 1 | 0 | 0 |
New-entrant sponsors: AO GENERIUM, Grünenthal GmbH, Keros Therapeutics, Inc..
Recently stopped trials
- NCT05689164 Pfizer - terminated: All participants who have received fordadistrogene movaparvovec in any Pfizer study will now be assessed for long-term safety in 1 combined A Study to Understand the Long-term Safety and Effects of an Experimental Gene Therapy for Duchenne Muscular Dystrophy.
- NCT06241950 Sarepta Therapeutics, Inc. - terminated: Study is being terminated due to a business decision. A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following I
- NCT01247207 PTC Therapeutics - terminated: Sponsor decision Study of Ataluren in Previously Treated Participants With Nonsense Mutation Dystrophinopathy (nmDBMD)
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2027-01 est. | P2 | Edgewise Therapeutics, Inc. EWTX | NCT05540860 A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX) | Duchenne Muscular Dystrophy | active not recruiting | 76 |
| 2027-01-31 est. | P2 | Daiichi Sankyo Co., Ltd. | NCT04433234 Long-term, Extension Study of DS-5141b in Patients With Duchenne Muscular Dystrophy | Duchenne Muscular Dystrophy | active not recruiting | 8 |
FDA decision events (last 12 months and upcoming)
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| 2027-01-21 | PDUFA date (company-disclosed) | pending | Dyne Therapeutics, Inc. DYN | rostudirsen | PDUFA January 21, 2027 - Dyne Therapeutics, Inc. (rostudirsen) |
| 2026-11-22 | PDUFA date (company-disclosed) | pending | CAPRICOR THERAPEUTICS, INC. CAPR | PDUFA November 22, 2026 - CAPRICOR THERAPEUTICS, INC. | |
| 2026-07-29 | FDA AdCom | held | Capricor, Inc. CAPR | AdCom 2026-07-29: Cellular, Tissue, and Gene Therapies Advisory Committee - BLA 125842 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-18 est. | P2 | Hoffmann-La Roche | NCT06450639 A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD) | Duchenne Muscular Dystrophy | active not recruiting | 30 |
| 2026-11-03 | P1/P2 | Solid Biosciences Inc. SLDB | NCT03368742 Microdystrophin Gene Transfer Study in Adolescents and Children With DMD | Duchenne Muscular Dystrophy | completed | 12 |
| 2026-10 est. | P1/P2 | Wave Life Sciences USA, Inc. WVE | NCT04906460 Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53) | Duchenne Muscular Dystrophy | active not recruiting | 25 |
| 2026-09-07 | P2 | Edgewise Therapeutics, Inc. EWTX | NCT05291091 Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON) | Becker Muscular Dystrophy | completed | 244 |
| 2026-09-07 | P3 | Sarepta Therapeutics, Inc. SRPT | NCT03992430 A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON) | Muscular Dystrophy, Duchenne | completed | 160 |
| 2026-09 est. | P2/P3 | REGENXBIO Inc. RGNX | NCT05693142 AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD) | Duchenne Muscular Dystrophy | active not recruiting | 65 |
| 2026-07-23 | P3 | Avidity Biosciences, Inc. | NCT06411288 Global Study of Del-desiran for the Treatment of DM1 | DM1; Myotonic Dystrophy; Myotonic Dystrophy 1; Myotonia; Myotonic Dystrophy Type 1 (DM1); Dystrophy | completed | 159 |
| 2026-06-18 | P3 | Taiho Pharmaceutical Co., Ltd. | NCT04587908 A Phase 3 Study of TAS-205 in Patients With Duchenne Muscular Dystrophy(REACH-DMD) | Duchenne Muscular Dystrophy | completed | 104 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "Duchenne muscular dystrophy"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.